About Imagenomix
Imagenomix Corp is a biotechnology company rooted in leading U.S. academic research, with a team strongly connected to Greek scientific talent. The company addresses a critical gap in oncology diagnostics, where pathology is central to cancer diagnosis and treatment decisions but often lacks timely and comprehensive molecular insights.
Imagenomix has developed an AI-driven approach that infers molecular genotypes directly from standard H&E pathology slides, eliminating the need for additional tissue samples and significantly reducing the typical multi-week turnaround time for results. It is also our first investment from the Brain Gain Fund.
